Evidence map›Paper›PMID 42094599›Full record

ArticleTheranostics2026

Edge-rich Cu-N

Xin Xing, Jiaji Yu, Yajie Zhang, Xue Chen, Liang Chen, Meng Du, Jie Ding, Zhiyi Chen, Li Li, Junjie Cheng

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xin XingDepartment of Stomatology, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu 241001, China.
Jiaji YuDepartment of Nutrition and Food Hygiene, School of Public Health; Department of Radiology, Zhongda Hospital, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology, School of Medicine; Southeast University, Nanjing 210009, China.
Yajie ZhangCentral Laboratory, Department of Biobank, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing 210022, China.
Xue ChenDepartment of Stomatology, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu 241001, China.
Liang ChenDepartment of Stomatology, The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College), Wuhu 241001, China.
Meng DuKey Laboratory of Medical Imaging Precision Theranostics and Radiation Protection, College of Hunan Province, Hengyang Medical School, The Affiliated Changsha Central Hospital, University of South China, Changsha, China.
Jie DingMax Planck Institute of Microstructure Physics, Weinberg 2, Halle, 06120, Germany.
Zhiyi ChenKey Laboratory of Medical Imaging Precision Theranostics and Radiation Protection, College of Hunan Province, Hengyang Medical School, The Affiliated Changsha Central Hospital, University of South China, Changsha, China.
Li LiMax Planck Institute of Microstructure Physics, Weinberg 2, Halle, 06120, Germany.
Junjie ChengDepartment of Nutrition and Food Hygiene, School of Public Health; Department of Radiology, Zhongda Hospital, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology, School of Medicine; Southeast University, Nanjing 210009, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rationale: Tumor catalytic therapy represents a promising antitumor approach by inducing ferroptosis and overcoming apoptosis-related resistance mechanisms. Its efficacy is primarily dictated by the extent of membrane lipid peroxidation (LPO). However, tumor cells may evade ferroptosis through metabolic reprogramming that enriches monounsaturated fatty acids (MUFAs) in membrane lipids, thereby diminishing oxidative vulnerability. Hence, strategies that simultaneously enhance catalytic ROS production and reprogram lipid metabolism are required to address this challenge. Methods: To overcome this limitation, a novel Cu-N Results: The Srl/ Conclusions: These results highlight the effectiveness of integrating edge-enriched single-atom catalysis with lipid metabolic modulation to enhance ferroptosis-based tumor therapy. The Srl/

Indexed as

Antineoplastic AgentsCopperLipid MetabolismNeoplasmsAnimalsCatalysisCell Line, TumorFemaleFerroptosisHumansLipid PeroxidationMetabolic ReprogrammingMiceReactive Oxygen SpeciesAntineoplastic AgentsCopperReactive Oxygen Speciescatalytic therapyferroptosisnanozymesingle atom catalysttumor therapy

Identifiers

PMID42094599
PMCPMC13142117

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.